Beam Therapeutics IncNASDAQ:BEAM
- LAST PRICE24.7200
- TODAY'S CHANGE (%)0.6000 (2.4876%)
- Bid / Lots24.7100/ 8
- Ask / Lots24.7800/ 8
- Open / Previous Close23.7500 / 24.1200
- Day Range
- 52 Week Range
- Volume256,506
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BEAM |
|---|---|---|
| 09:32 ET | 7475 | 23.98 |
| 09:35 ET | 3291 | 23.99 |
| 09:37 ET | 5418 | 23.875 |
| 09:39 ET | 6132 | 23.95 |
| 09:42 ET | 1001 | 24.08 |
| 09:44 ET | 5310 | 23.975533 |
| 09:46 ET | 614 | 23.99 |
| 09:48 ET | 3311 | 23.98 |
| 09:50 ET | 11812 | 23.99 |
| 09:51 ET | 806 | 24 |
| 09:53 ET | 1600 | 24.04 |
| 09:55 ET | 2405 | 24.04 |
| 09:57 ET | 800 | 23.985 |
| 10:00 ET | 4320 | 24.075 |
| 10:02 ET | 3107 | 23.79 |
| 10:04 ET | 500 | 23.82 |
| 10:06 ET | 712 | 23.885 |
| 10:08 ET | 644 | 23.825 |
| 10:09 ET | 600 | 24 |
| 10:11 ET | 450 | 24.15 |
| 10:13 ET | 1565 | 24.24 |
| 10:15 ET | 2655 | 24.25 |
| 10:18 ET | 4030 | 24.33 |
| 10:20 ET | 19434 | 24.4 |
| 10:22 ET | 4741 | 24.4 |
| 10:24 ET | 13830 | 24.4042 |
| 10:26 ET | 1100 | 24.49 |
| 10:27 ET | 100 | 24.515 |
| 10:29 ET | 700 | 24.51 |
| 10:31 ET | 700 | 24.41 |
| 10:33 ET | 600 | 24.475 |
| 10:36 ET | 300 | 24.485 |
| 10:38 ET | 576 | 24.53 |
| 10:40 ET | 100 | 24.525 |
| 10:42 ET | 700 | 24.4 |
| 10:44 ET | 508 | 24.44 |
| 10:45 ET | 200 | 24.4208 |
| 10:47 ET | 17050 | 24.36 |
| 10:49 ET | 2104 | 24.36 |
| 10:51 ET | 700 | 24.375 |
| 10:54 ET | 400 | 24.43 |
| 10:56 ET | 600 | 24.41 |
| 10:58 ET | 600 | 24.43 |
| 11:00 ET | 500 | 24.49 |
| 11:02 ET | 800 | 24.495 |
| 11:03 ET | 2322 | 24.4 |
| 11:05 ET | 1500 | 24.51 |
| 11:07 ET | 1700 | 24.49 |
| 11:09 ET | 400 | 24.5 |
| 11:12 ET | 825 | 24.47 |
| 11:14 ET | 2272 | 24.41 |
| 11:16 ET | 1564 | 24.495 |
| 11:18 ET | 567 | 24.5 |
| 11:20 ET | 562 | 24.627798 |
| 11:21 ET | 2200 | 24.585 |
| 11:23 ET | 100 | 24.55 |
| 11:25 ET | 978 | 24.58 |
| 11:27 ET | 600 | 24.61 |
| 11:30 ET | 200 | 24.61 |
| 11:32 ET | 749 | 24.64 |
| 11:34 ET | 873 | 24.71 |
| 11:36 ET | 581 | 24.675 |
| 11:38 ET | 1200 | 24.75 |
| 11:39 ET | 300 | 24.74 |
| 11:41 ET | 300 | 24.77 |
| 11:43 ET | 1066 | 24.69 |
| 11:45 ET | 840 | 24.6495 |
| 11:48 ET | 302 | 24.6093 |
| 11:50 ET | 100 | 24.58 |
| 11:52 ET | 500 | 24.55 |
| 11:54 ET | 1400 | 24.555 |
| 11:56 ET | 400 | 24.54 |
| 11:57 ET | 846 | 24.57 |
| 11:59 ET | 2721 | 24.59 |
| 12:01 ET | 500 | 24.56 |
| 12:03 ET | 300 | 24.53 |
| 12:06 ET | 827 | 24.54 |
| 12:08 ET | 1121 | 24.565 |
| 12:12 ET | 2283 | 24.685 |
| 12:14 ET | 100 | 24.675 |
| 12:15 ET | 721 | 24.65 |
| 12:17 ET | 5300 | 24.66 |
| 12:19 ET | 200 | 24.64 |
| 12:21 ET | 400 | 24.58 |
| 12:24 ET | 1500 | 24.53 |
| 12:26 ET | 600 | 24.53 |
| 12:28 ET | 1000 | 24.63 |
| 12:30 ET | 100 | 24.69 |
| 12:32 ET | 300 | 24.74 |
| 12:33 ET | 200 | 24.73 |
| 12:35 ET | 500 | 24.72 |
| 12:37 ET | 502 | 24.695 |
| 12:39 ET | 300 | 24.62 |
| 12:42 ET | 960 | 24.72 |
Nov 12, 2024
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 7, 2024
DJ Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 5:01AM ET on Thursday Nov 07, 2024 by Dow Jones
5:01AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
DJ Beam Therapeutics Is Maintained at Sector Perform by RBC Capital, from 11:10AM ET on Wednesday Nov 06, 2024 by Dow Jones
11:10AM ET on Wednesday Nov 06, 2024 by Dow JonesDJ Beam Therapeutics Raised to Outperform From Market Perform by Leerink Partners, from 7:39AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:39AM ET on Wednesday Nov 06, 2024 by Dow Jones
Nov 5, 2024
Press Release: Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting, from 9:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
9:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Beam Therapeutics Inc | 2.0B | -14.4x | --- |
Genmab A/S | 13.7B | 20.3x | +22.71% |
Galapagos NV | 1.8B | -28.0x | --- |
Catalyst Pharmaceuticals Inc | 2.5B | 18.1x | --- |
BioCryst Pharmaceuticals Inc | 1.5B | -11.9x | --- |
Twist Bioscience Corp | 2.4B | -11.4x | --- |
Company Information
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Contact Information
- Headquarters
- 238 Main StreetCAMBRIDGE, MA, United States 02142
- Phone
- 857-327-8775
- Fax
- 302-655-5049
Executives
- President
- Giuseppe Ciaramella
- Chief Executive Officer, Principal Financial and Accounting Officer, Director
- John Evans
- Chief Medical Officer
- Amy Simon
- Chief Legal Officer and Secretary
- Christine Bellon
- Lead Independent Director
- Mark Fishman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.0B |
|---|---|
Revenue (TTM) | $349.6M |
Shares Outstanding | 82.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.87 |
EPS | $-1.72 |
Book Value | $12.02 |
P/E Ratio | -14.4x |
Price/Sales (TTM) | 5.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -52.25% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
